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Fig 1
Conclusion: This study confirms higher mortality of AMI patients admitted on
weekends in the beginning of the decade;The difference in mortality of AMI is not
observed in recent years reflecting improved care.
TCT-338
Associations between symptom-to-door time and biomarkers on 12-month
mortality in patients with acute myocardial infarction
Jang Hoon Lee, Kyun Hee Kim, Won Suk Choi, Sun Hee Park, Dong Heon Yang,
Hun Sik Park, Yongkeun Cho, Shung Chull Chae, Jae Eun Jun
Kyungpook National University Hospital, Daegu, Republic of Korea
Background: Little is known about the associations between symptom-to-door (STD)
time and biomarkers including N-terminal pro-B type natriuretic peptide (NT-proBNP)
and high sensitivity C-reactive protein (hs-CRP) in patients with acute myocardial
infarction (AMI).
Methods: Between November 2005 and February 2010, 1,233 patients were followed
up more than 12-month after their AMI and finally analyzed in this study. The patients
who had STD time more than 3 days were excluded from this study. Patients were
categorized into 3 groups based on their STD time; Group I (STD time < 6-hour,
n=767), Group II (6-hour ≤ STD time ≤ 12-hour, n=181), and Group III (STD time >
12-hour, n=285).
Results: The 12-month mortality was significantly higher in Group III (13.7%)
compared to Group I (9.3%) and Group II (11.0%)(p for trend = 0.037). The serum
levels of log-transformed NT-proBNP were significantly higher in Group III (7.48±1.70
pg/mL) compared to Group I (5.77±2.06 pg/mL) and Group II (6.64±1.73 pg/mL)(p
for trend<0.001). The serum levels of log-transformed hs-CRP were also significantly
higher in Group III (1.72±1.74 mg/L) compared to Group I (0.87±1.55 mg/L) and
Group II (1.21±1.69 mg/L)(p for trend<0.001). The patients with symptomatic heart
failure at admission (Killip class >2) were significantly higher in Group III (p=0.041),
and left ventricular ejection fraction was significantly higher in Group I (p=0.006). In
Cox proportional hazards model, Group III (crude hazard ratio [HR] 1.516, 95%
confidence interval [CI] 1.026-2.241, p =0.037) had significantly higher 12-month
mortality compared with Group I. In Group III, elevated serum levels of log-
transformed NT-pro BNP (HR 2.761, 95% CI 1.084-7.036, p =0.033), not
log-transformed hs-CRP, in addition to age (HR 1.114, 95% CI 1.025-1.210, p =0.011)
and body mass index (HR 1.423, 95% CI 1.087-1.864, p =0.010) were independent
predictors of 12-month mortality after adjustment for confounding variables.
Conclusion: The STD time is significantly associated with the serum levels of NT-
proBNP and hs-CRP, and NT-proBNP is independent predictor of 12-month mortality,
particularly in patients with longer STD time.
TCT-339
Transradial Intervention Procedure for Un-Shock, ST Segment Elevation
Myocardial Infarction Patients with Palpable Radial Artery
Hung Minh Ngo, Nhan T Vo
Interventional Cardiology, Choray Hospital, Ho Chi Minh City, Viet Nam
Background: Primary Percutaneous Coronary Intervention (PPCI) which is most
performed via Trans-Femoral Intervention Procedure (TFIP) is currently a standard of
care. Trans-Radial Intervention Procedure (TRIP) has been emerging around the world
as an alternative approach in both elective and primary angioplasty. We examine
whether TRIP which provides efficacy, less bleeding and more comfortable for patient
is as feasible as the standard TFIP.
Methods: A total of 524 consecutive patients who underwent PPCI for STEMI from
1/2009 to 12/2010 were enrolled into cross-sectional study. Patients who were un-
shock and had palpable radial pulses were randomly assigned to receive TRIP and TFIP
for primary angioplasty. The study endpoints were partial and total procedure,
fluoroscopy time (minute), and amount of contrast media (ml).
Results: There were 249 and 275 patients in TRIP and TFIP groups respectively. All
patients were pretreated with dual antiplatelet therapy and heparin regimen of 60U/kg.
The baseline clinical characteristics was comparable between the 2 groups. Preparation
(9.75±4.33 vs 8.92±4.10; p=0.25), aortic root approach (2.28±2.47 vs 2.12±2.57;
p=0.474), engagement (1.78±1.84 vs 1.56±1.31; p=1.31), revascularization
(15.25±6.90 vs 14.50 ±7.36; p=0.242) time and contrast media (155.64±44.42 vs
153.62±103.62; p=0.79) were comparable between the 2 groups. Puncture time was
in-favor for TRIP (3.06±2.57 vs 2.37±2.45; p=0.003) and as a result, lab door-to-
balloon time in TFIP group was shorter than TRIP group (22.13±8.623 vs 20.21±8.006;
p=0.011). Fluoroscopy time in TRIP group was also longer than TFIP group
(10.08±6.58 vs 8.18±4.24; p=0.001). However, total procedure time was statistically
comparable between the two groups (51.09±15.63 vs 48.50±15.71).
Conclusion: TRIP showed statistically non-inferior to TFIP on almost procedural
parameters during PPCI for un-shock STEMI patients with palpable radial artery.
Although puncture and fluoroscopy time of TRIP remained a short gap to TFIP, TRIP
is really feasible and can be considered as alternative approach in PPCI.
TCT-340
Efficacy and Safety Of The M-Guard Stent In Primary Percutaneous Coronary
Intervention for ST-Elevation Myocardial Infarction
Prodromos Anthopoulos, Ioannis Alexanian, Loukas Pappas, Georgia Karabela,
Josef Moutiris, Costantine Michas, Anastasios Salahas, George Yfantis, Ioannis
Antonellis, Antonios Polydorou
Cath Lab, Evagelismos General Hospital, Athens, Greece
Background: In recent years many strategies have been developed to treat
intracoronary thrombus in STEMI patients undergoing primary PCI. M-Guard(MGS),
is a bare metal stent covered by a thin polymer mesh on its external surface, designed
to trap thrombus between the stent and vessel wall, providing embolic protection. Aim
of this study was to evaluate the effectiveness and safety of MGS at 30 days and 1 year
after pPCI and compare its short term results to a control group from the pre MGS era.
We also examined if the benefit from the use of MGS was independent from the use
of thrombus aspiration(TA) during pPCI.
Methods: 73 consecutive STEMI patients with visible thrombus who underwent pPCI
were enrolled in the study [63.4±13.5 years,men:53]. MGS was successfully placed in
68(93.1%). TA (24/68-35.29%) and balloon predilation (35/68-51.47%) was at the
operators discretion. This group was retrospectively compared with 44 consecutive
STEMI patients who underwent pPCI before the introduction of TA or the MGS. They
served as control group. No differenceses between the 2 groups in baseline
characteristics.
Results: Target vessel revascularization was 0/68 at 30 days and 4/68(5.88%) at 1 year.
Cardiac deaths:0/68 at 30 days and 2/68 at 1 year, both possible stent thrombosis.
TIMI3 was achieved in 62/68(91.17%). Final TIMI was 2.88±0.53 in the MGS group
vs 2.53±0.88 in the control group(p: 0.015). Myocardial Blush Grade(MBG) was
2.36±0.91 vs 1.83±1.21 (p: 0.009) at the end of pPCI respectively. No-reflow
phenomenon occurred in 2/68 patients in the MGS group vs 8/44 in the control
(p:0.008). The subgroup of patients from the MGS group that TA was not performed
were 44 individuals. Final TIMI for them was 2.9±0.3 (p:0.01), compared to the control
group and MBG:2.43±0.88 (p:0.009). No-reflow:0/44,(p:0.006).
Conclusion: -In the setting of pPCI, MGS exhibited low TVR and thrombosis rates at
1 and 12 months, in the high risk group of STEMI patients. -With the use of MGS final
TIMI flow and MBG are higher and the no-reflow incidence lower. -The benefit from
the use of MGS is independent from TA.
TCT-341
Prognostic Consequence of Periprocedural Hemoglobin Decrease with and
without Observed Blood Loss in Patients with ST-elevation Myocardial
Infarction Undergoing Primary Percutaneous Coronary Intervention
Wouter J Kikkert, Sophie H van Nes, Alexander MacLeod Manuel, Krystien Lieve,
Marije Vis, Jan Baan, Karel Koch, Robbert J de Winter, Jan J Piek, Jan G Tijssen,
Jose P Henriques
Academic Medical Center, Amsterdam, Netherlands
Background: Little is known regarding the frequency and sequelae of periprocedural
hemoglobin (Hb) drops with and without observed blood loss in patients undergoing
primary PCI (pPCI) for STEMI. We sought to establish the prognostic value of a
periprocedural Hb decrease with and without observed bleeding.
Methods: We assessed the occurrence of periprocedural hemoglobin decrease with
and without observed blood loss occurring within 10 days from index pPCI, in 1762
consecutive STEMI patients undergoing pPCI between 1-1-2003 and 31-8-2008, in a
large tertiary PCI center. Patients presenting in shock were excluded from our analysis
(final cohort n = 1602). Bleeding and bleeding source were recorded from chart review.
A periprocedural Hb decrease was calculated by subtracting the nadir Hb during index
admission (within 10 days from index procedure) from the baseline Hb. The primary
endpoint was one-year all-cause mortality. The prognostic values of a periprocedural
Hb decrease with and without observed blood loss were calculated using stepwise Cox
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proportional Hazards models, including the following candidate covariables: age, sex,
diabetes, hypertension, hypercholesterolemia, current smoking, prior PCI, prior CABG,
previous MI, baseline creatinin clearance, baseline Hb, heart rate and systolic blood
pressure, peak CK-MB release and multivessel disease.
Results: Of 1602 patients with STEMI, 147 patients (9.3 %) developed a Hb decrease
> 4 g/dL. Of these, no bleeding focus could be established in 54 patients (3.4 %).
Patients with a Hb decrease ≥ 4 g/dL had a HR 1.61 (95 % CI 0.84 – 3.09, p 0.15) for
one year mortality if blood loss was observed, and a HR 3.18 (95% CI 1.49 – 6.76, p
= 0.003) if no blood loss was observed.
Conclusion: A periprocedural hemoglobin decrease irrespective of observed bleeding
represents a strong independent predictor for one year mortality. Compared with
patients who suffered observed blood loss, patients without observed blood loss had a
higher risk for one year mortality.
TCT-342
Accuracy of Acef, Euroscore and Syntax Score in Risk Stratification of Elderly
(≥70years) Patients Undergoing Primary Angioplasty
Flavia Ballocca1, Chiara Resmini1, Marco Di Cuia1, Sara Sturnia1, Fabrizio
D’Ascenzo1, Mario Bollati1, Claudio Moretti1, Filippo Sciuto1, Pier Luigi Omedè1,
Giuseppe Biondi Zoccai2, Imad Sheiban1, Fiorenzo Gaita1
1Ospedale S.Giovanni Battista Torino, Torino, Italy; 2Division of Cardiology
University of Modena and Reggio Emilia, Modena, Italy
Background: With increasing life expectancy the management of acute myocardial
infarction (AMI) in patients of an older age is of growing importance. However, data
are limited regarding risk stratification of ST-segment elevation myocardial infarction
(STEMI) in elderly people (≥70years). We thus performed a retrospective study to
compare the accuracy of three risk scores - ACEF, EuroSCORE and SYNTAX Score
- in subjects <70 and ≥70 years with STEMI.
Methods: We included 100 patients undergoing primay PCI at our centre from July
2002 to December 2005.We compared the accuracy in predicting MACE of the three
scores both in patients ≥70years and <70years using ROC curves and matching Areas
Under Curves (AUC).
Results: We included a total of 100 patients, 36 ≥70years and 64 <70years. The
percentages of male subjects (72.22% vs 93.75%, p=0.0029) and previous AMI (0%
vs 11.11%, p=0.0097) were higher in the <70 group, while in-stent restenosis (5.55%
vs 0%, p=0.0267) was more frequent in older patients. In patients ≥70years the best
predictor for MACE is SYNTAX Score (AUC 0.628, 95%CI 0.452- 0.783), followed
by ACEF (AUC 0.560, 95%CI 0.385-0.725) and EuroSCORE (AUC 0.536, 95%CI
0.362-0.703), but they do not differ significantly (ACEF vs EuroSCORE p=0.784,
ACEF vs SYNTAX Score p=0.616, EuroSCORE vs SYNTAX Score p=0.428). In
patients <70years better accuracy is shown by SYNTAX Score (AUC 0.613, 95%CI
0.483-0.732), than EuroSCORE (AUC 0.591, 95%CI 0.461-0.713) and ACEF (AUC
0.560, 95%CI 0.430-0.683), without a statistically significant difference (ACEF vs
EuroSCORE p=0.567, ACEF vs SYNTAX Score p=0.541, EuroSCORE vs SYNTAX
Score p=0.800).
Conclusion: All the assessed scores (ACEF, EuroSCORE and SYNTAX Score) have
a good accuracy in risk stratification of patients with STEMI undergoing primary PCI.
The greatest results in predicting MACE in both groups (≥70years and <70years) are
shown by SYNTAX Score; consequently SYNTAX Score might be proposed as a
scoring system to be used in both youger and older patients in the emergency setting.
TCT-343
In-Hospital Mortality of Patients Undergoing Primary Percutaneous Coronary
Intervention: Validation of the EuroHeart STEMI PCI Score
Ana Belen Cid Alvarez, Ramiro Trillo Nouche, Melisa Santas Alvarez, Diego Lopez
Otero, Raimundo Ocaranza Sanchez, Pablo Souto Castro, Rosa Agra Bermejo,
Francisco Gude Sampedro, Jose Ramon Gonzalez Juanatey
Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela,
Spain
Background: A new scoring system, the EuroHeart score (EHs), was developed
recently in patients included in the PCI registry of the Euro Heart Survey. We assessed
the validity of this risk score in a contemporary cohort of patients admitted to our
hospital with ST elevation myocardial infarction (STEMI) who were undergoing
primary percutaneous coronary intervention (PPCI).
Methods: The study included 310 consecutive patients undergoing PPCI between
January 2009 and December 2010.The validity of the EHs was evaluated by assessing
its calibration using the Hosmer-Lemeshow test and its discriminatory capacity was
evaluated using the area under the ROC curve.
Results: The median patient age was 66 years, 73% were men and 26.5% had diabetes.
Percutaneous access was via the radial approach in 72% of the patients. The culprit
artery was the left anterior descending in 42.7% of the patients,31% had three-vessel
disease and a stent was implanted in 90% of the patients. The median EHs STEMI PCI
was 16[11–21]. We divided the patients into tertiles: EHs(1)≤14; EHs(2) >14 and ≤18;
EHs(3) >18. In-hospital mortality was 10.6%: 1% in EHs (1), 2% in EHs (2), and 3.7%
in EHs (3) (P<0.05). The EHs levels were an independent determinant of in-hospital
mortality in a multivariate analysis (HR IC95%: 1.164 (1.115–1.214), P<0.05). The
calibration of the EHs STEMI PCI was good (Hosmer-Lemeshow, P>0.5), and its
discriminatory capacity was excellent, with an area under the ROC curve of 0.91 (0.86–
0.97)
Conclusion: The EHs STEMI PCI for predicting in-hospital mortality was validated
in our cohort of patients. The EHs is easy to implement in clinical practice and is very
useful for the stratification of this group of patients.
TCT-344
Post-discharge Bleeding and Thienopyridine Discontinuation among AMI
Patients Treated with PCI: Insights from the TRANSLATE-ACS Study
Tracy Y Wang1, Emily Honeycutt1, Timothy D Henry2, Mark B Effron3, John C
Messenger4, David J Cohen5, Daniel B Mark1, Gregg W Stone6, Mandeep Singh7,
Maurice Rozek8, Gregg C Fonarow9, Eric D Peterson1
1Duke Clinical Research Institute, Durham, NC; 2Minneapolis Heart Institute
Foundation at Abbott Northwestern Hospital, Minneapolis, MN; 3Eli Lilly &
Company, Indianapolis, IN; 4University of Colorado School of Medicine, Aurora,
CO; 5Saint Luke’s Mid America Heart Institute, Kansas City, MO; 6Columbia
University Medical Center/New York Presbyterian Hospital and the Cardiovascular
Research Foundation, New York, NY; 7Mayo Clinic, Rochester, MN; 8Daiichi-
Sankyo, Inc., Parsippany, NJ; 9UCLA Medical Center, Los Angeles, CA
Background: Patients with AMI treated with PCI require long-term thienopyridine
therapy, yet the incidence of post-discharge bleeding and its association with
thienopyridine discontinuation in real-world practice is unknown.
Methods: TRANSLATE-ACS is an ongoing registry of AMI patients treated with PCI
and thienopyridine therapy. We examined the incidence of patient-reported “severe,
unexplained bruising or bleeding” by 6 weeks post-discharge, and bleeding-associated
thienopyridine cessation and rehospitalization (verified by billed diagnosis codes).
Results: Among 2177 AMI patients (53% STEMI) treated with PCI and discharged
on a thienopyridine, 322 (15%) reported any bleeding within 6 weeks post-discharge.
Patients enrolled to date who reported bleeding were younger (median 58 vs. 60 years,
p=0.04) and more likely to be female (40 vs. 26%, p<0.0001) than those without
bleeding. Between groups, there were no differences in MI type (STEMI vs. NSTEMI)
and in-hospital bleeding rates. Nuisance bleeding, such as severe bruising and nose
bleeds, were the most frequent bleeding complaints (Table). However, by 6 weeks post-
discharge, only 12 (3.7%) of 322 patients reporting bleeding required hospitalization
for bleeding and only 1 of these hospitalized patients stopped thienopyridine therapy
(due to thrombocytopenia). Among non-rehospitalized patients who reported bleeding,
4 patients (1.2%) had stopped thienopyridine therapy due to bleeding by 6 weeks.
Conclusion: While nuisance bleeding or bruising is a frequent complaint during the
early post-discharge time period among PCI-treated AMI patients, bleeding is only
rarely associated with antiplatelet therapy discontinuation or rehospitalization.
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